NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

CELLULAR HIV-DNA LOAD PREDICTS THE OUTCOME OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART).

Hatzakis A, Touloumi G, Pantazis N, Anastassopoulou C, Katsarou O, Karafoulidou A, Goedert JJ, Kostrikis LG; IAS Conference on HIV Pathogenesis and Treatment (2nd : 2003 : Paris, France).

Antivir Ther. 2003; 8 (Suppl.1): abstract no. 480.

Department of Hygiene and Epidemiology, Athens University Medical School, Athens, Greece

Human immunodeficiency virus type 1 proviral DNA or cellular HIV-DNA load is an independent marker of disease progression [Kostrikis et al. J. Virol. 2002; 76(20):10099-10108]. We assessed whether cellular HIV DNA before initiation of HAART can predict its outcome. Study subjects included all 53 haemophiliacs of the Greek component of the Multicenter Hemophilia Cohort Study for whom PBMCs were available before and after HAART. Cellular HIV DNA was quantified by a molecular beacon-based real-time PCR assay in multiple samples per patient with a median (IQR) follow-up of 74 (45, 101) weeks. The median (range) baseline HIV DNA load was 291 (<10, 3468) copies per 10(6 )PBMCs. Baseline HIV DNA load did not predict initial virological response (IVR). None of the patients with IVR and baseline HIV DNA load below the median experienced a subsequent virological rebound (VRB), while the cumulative probability of VRB by week 104 was 55% among those with HIV DNA load greater than the median (P=0.003). Cellular HIV DNA load was the only parameter associated with sustained virological response as shown by univariate or multivariate analyses after adjustment for age at seroconversion, age at HAART initiation, HIV RNA, CD4 and previous AIDS diagnosis [OR (95% CI) 0.243 (0.067, 0.887), P=0.032]. The half-life of HIV DNA load was found to be 7.9 months and 59 months for patients with SVR and VFL, respectively (P=0.036). These data suggest that cellular HIV DNA load is a marker of virological rebound in patients with initial viral response and it can reliably predict the long-term success of HAART.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Acquired Immunodeficiency Syndrome
  • Antiretroviral Therapy, Highly Active
  • DNA
  • DNA, Viral
  • Disease Progression
  • HIV Infections
  • HIV Seropositivity
  • HIV-1
  • Hemophilia A
  • Humans
  • Polymerase Chain Reaction
  • virology
Other ID:
  • GWAIDS0023139
UI: 102262763

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov